Status:
COMPLETED
Mesalazine (PENTASA®) in Ulcerative Colitis
Lead Sponsor:
Ferring Pharmaceuticals
Collaborating Sponsors:
Ferring Arzneimittel GmbH
Conditions:
Ulcerative Colitis
Eligibility:
All Genders
18+ years
Brief Summary
This non-interventional study examines whether the patient's level of information and the consideration of the patient's preference have a positive effect on the compliance and thus also on the therap...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients are treated for the first time with oral PENTASA®, e.g. following first diagnosis of ulcerative colitis for treatment of an acute episode or
- Following a therapy-free period (no previous mesalazine therapy) or due to poor response or underdosage oder lacking acceptance of the previous medication the patients are re-adjusted to oral PENTASA®,
- The patients (≥ 18 years) have been informed about the NIS and have given their written consent for participation.
Exclusion
Key Trial Info
Start Date :
February 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
506 Patients enrolled
Trial Details
Trial ID
NCT01517607
Start Date
February 1 2012
End Date
December 1 2013
Last Update
October 1 2015
Active Locations (149)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational site, Wettinerstraße 22
Altenburg, Germany
2
Investigational site, Marienstraße 6
Amberg, Germany
3
Investigational site, Adam-Ries-Straße 57c
Annaberg-Buchholz, Germany
4
Investigational site, Goethestraße 5
Ansbach, Germany